KARA LINDEMAYER: Open Payments
NPI 1376099416 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$486 in 24 payments from 4 companies in 2025. Trend: 2023 $51 · 2024 $140 · 2025 $486
Food & beverage: $486
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $373 |
| ACADIA Pharmaceuticals Inc | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
Products named: INGREZZA, NUPLAZID, AUSTEDO XR, REXULTI.
Industry payments across TX — which companies pay providers there.
